3Dombrovskiv VY,Martin AA,Sunderram J,et al.Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003.Crit Care Med,2007,35 (5): 1244 1250.
1Dellinger P, Carlet JM, Masur H, et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med, 2004, 30: 536-555.
2Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med, 2001, 345: 1368-1377.
3Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest, 2002, 122: 262-268.
4The SAFE Study Investigators. A Comparison of Albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med, 2004, 350:2247-2256.
5De Backer D, Creteur J, Silva E, et al. Effects of dopamine,norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best? Crit Care Med, 2003, 31:1659-1667.
6Kellum J, Decker J. Use of dopamine in acute renal failure: a metaanalysis. Crit Care Med, 2003, 31: 1526-1531.
7Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA, 2002, 288:862-871.
8Van Den Berghe G, Wouters PJ, Bouillon R, et al. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control Crit Care Med, 2003, 31: 359-366.
9Bernard GR, Vincent JL, Laterre PF, et al. Recombinant human protein C worldwide evaluation in severe sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med, 2001,344: 699-709.
10Cole L, Bellomo R, Joumois D, et al. High-volume haemofiltration in human septic shock. Intensive Care Med, 2001, 27:978-986.
